刘艺，汉族，中共党员。毕业于北京中医药大学中药药剂学专业，获医学博士学位，获“北京市优秀毕业生”荣誉称号。现任天津中医药大学中药学院药物制剂教研室专任教师。主要研究方向为中药制剂安全性评价，主持国家中医药考试科研课题1项，主持天津市2025年自然科学基金重点项目1项，主持横向课题1项，以骨干参与其他科研项目8项；以第一作者或通讯作者在Journal of Ethnopharmacology, Biomedicine & Pharmacotherapy, Industrial Crops & Products等SCI杂志发表学术论文近20篇；作为主要发明人申请专利6项，2项已授权；现任中华中医药学会中药制剂分会青年委员。
主讲《中药药剂学》《生物药剂学》《生物药剂学与药物动力学》《中药制剂专论》等课程；主持完成省部级教改课题1项；参编行业规划教材3部；以第一作者或通讯作者发表教改论文2篇。2024年荣获天津高校第十七届青年教师教学竞赛理科组三等奖；2026年获第六届全国高校教师教学创新大赛天津赛区三等奖；作为第一指导教师获得天津市创新创业类比赛金奖1项、银奖1项、铜奖2项。
主要代表性成果：
[1] Xiaoran Zhao, Zicheng Ma, Meiqi Liu, Ruimeng Zhao, Huixian Qing, Chuang Li, Lili Sun, Yi Liu*, Shiwei Chai*, Xiaoliang Ren*. Chemometric strategies for binary discrimination and one-class classification of medicinal parts of Angelicae Sinensis Radix by fusing chemical profiles with anticoagulant activity[J]. Industrial Crops & Products, 2026, 246: 123410.（1区，IF=6.2）
[2] Yu Yin, Xuerou Wei, Yongjian Song, Jue Zhuang, Liying Liu, Yanan Liu*, Yi Liu*, Meng Wang*, Xiaoliang Ren. Quality Evaluation of Astragalus Membranaceus Based on Polysaccharide Fingerprinting and Chemometric Analysis [J]. International Journal of Biological Macromolecules, 2026, 339: 149726.（2区Top，IF=8.5）
[3] Yongjian Song, Bokai Zhang, Xi Zhao, Xuerou Wei, Liying Liu, Yi Liu*, Xiaoliang Ren*. A study on the compatibility mechanism of Dahuang-Gancao decoction based on liquid-phase state and biopharmaceutics[J]. Journal of Ethnopharmacology, 2025, 350.（中科院大类2区Top，IF=5.4）
[4] Meiqi Liu, Xiaoran Zhao, Jinli Wen, Lili Sun, Rui Huang, Huijie Zhang*, Yi Liu*, Xiaoliang Ren*. A multidimensional strategy for uncovering comprehensive quality markers of Scutellariae Radix based on UPLC-Q-TOF-MS analysis, artificial neural network, network pharmacology analysis, and molecular simulation[J]. Frontiers in Plant Science, 2024, 1423678.（2区Top，IF=6.6）
[5] [4]Guoqin Zhang, Jianhua Sun, Meiqi Liu, Zhixiang Tian, Zicheng Ma, Bingyu Hao, Jintang Ning, Xiaoliang Ren, Meng Wang, Ping Wang, Jiunian Li, Hailin Li, Jian Ni*, Yi Liu*. Polygoni multiflori radix exacerbates idiosyncratic inflammatory liver injury through the FXR-SHP pathway and altered pharmacokinetic behavior[J]. Biomedicine & Pharmacotherapy, 2023, 160: 114233.（2区Top，IF=7.5）
